1. Ademi Firm investigates Repare for possible fiduciary duty violations. 2. Repare shareholders expected to receive $1.82 per share at closing. 3. Transaction limits competing bids, raising concerns about board decisions. 4. Insiders benefit substantially from change of control arrangements.
Investigations into fiduciary duties could lead to stock volatility and shareholder distrust. Historical examples include negative market reactions to similar investigations.
The ongoing investigation affects Repare's governance and can impact investor confidence significantly.
The immediate investigation creates market uncertainties that could influence stock price quickly.
MILWAUKEE, Nov. 14, 2025 /PRNewswire/ -- The Ademi Firm is investigating Repare (NASDAQ:RPTX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with XenoTherapeutics, Inc.
Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.
In the transaction, Repare shareholders will receive an estimated $1.82 per share in cash at closing, based on the company's current estimates. The final payment amount will be determined by Repare's cash balance at closing after deducting transaction costs and outstanding liabilities. Additionally, shareholders will receive one non-transferable contingent value right (CVR) per share, entitling them to portions of future proceeds from existing partnerships and potential asset dispositions. The CVRs provide varying percentages of net proceeds from partnerships with Bristol-Myers Squibb, Debiopharm and DCx Biotherapeutics, ranging from 90% to 75% depending on timing over a 10-year period.
Repare insiders will receive substantial benefits as part of change of control arrangements.
The transaction agreement unreasonably limits competing transactions for Repare by imposing a significant penalty if Repare accepts a competing bid. We are investigating the conduct of the Repare board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi & Fruchter LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders-302616105.html
SOURCE Ademi LLP